Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10319468 | 1.00 | BACE1 (0.53) | BACE1ABCB1SYKMEN1KMT2A | |
| SCHEMBL10319466 | 1.00 | BACE1 (0.53) | BACE1ABCB1SYKMEN1KMT2A | |
| SCHEMBL11889620 | 0.86 | L3MBTL1 (0.49) | POLBL3MBTL1OPRK1MAPT | |
| SCHEMBL18297341 | 0.86 | L3MBTL1 (0.49) | POLBL3MBTL1OPRK1MAPT | |
| SCHEMBL10318194 | 0.84 | OPRK1 (0.50) | MEN1KMT2APOLBL3MBTL1OPRK1 | |
| SCHEMBL10321630 | 0.84 | OPRK1 (0.50) | MEN1KMT2APOLBL3MBTL1OPRK1 | |
| SCHEMBL16468969 | 0.83 | GPR119 (0.52) | SYKMEN1KMT2AGPR119POLB | |
| SCHEMBL16468970 | 0.83 | GPR119 (0.52) | SYKMEN1KMT2AGPR119POLB | |
| SCHEMBL29889007 | 0.83 | SIGMAR1 (0.56) | BACE1MEN1KMT2AP2RX7MAPT | |
| SCHEMBL23853723 | 0.83 | BACE1 (0.56) | BACE1ABCB1SYKMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2776431-B1 | 2-OXO-OXAZOLIDIN-3,5-DIYL ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2016-05-04 | — | — | EP | disclosed |
| US-9079922-B2 | 2-oxo-oxazolidin-3,5-diyl antibiotic derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2015-07-14 | — | — | US | disclosed |
| US-20150051188-A1 | 2-OXO-OXAZOLIDIN-3,5-DIYL ANTIBIOTIC DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-02-19 | — | — | US | disclosed |
| CN-102421778-B | Dihydropteridinone derivatives, preparation process and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO | 2013-10-16 | — | — | CN | disclosed |
| CN-102421778-A | Dihydropteridinone derivatives, preparation process and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO | 2012-04-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051188-A1 | 2-OXO-OXAZOLIDIN-3,5-DIYL ANTIBIOTIC DERIVATIVES | OXA1L, PYM1, MRPL21 | BACE1 1925/4885ABCB1 1423/4885SYK 1902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.